PuSH - Publikationsserver des Helmholtz Zentrums München: The <em>CTRB1/2</em> locus affects diabetes susceptibility and treatment via the incretin pathway.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

't Hart, L.M.* ; Fritsche, A. ; Nijpels, G.* ; van Leeuwen, N.* ; Donnelly, L.A.* ; Dekker, J.M.* ; Alssema, M.* ; Fadista, J.* ; Carlotti, F.* ; Gjesing, A.P.* ; Palmer, C.N.* ; van Haeften, T.W.* ; Herzberg-Schäfer, S.A.* ; Simonis-Bik, A.M.C.* ; Houwing-Duistermaat, J.J.* ; Helmer, Q.* ; Deelen, J.* ; Guigas, B.* ; Hansen, T.* ; Machicao, F.* ; Willemsen, G.* ; Heine, R.J.* ; Kramer, M.H.* ; Holst, J.J.* ; de Koning, E.J.* ; Häring, H.-U. ; Pedersen, O.* ; Groop, L.* ; de Geus, E.J.* ; Slagboom, P.E.* ; Boomsma, D.I.* ; Eekhoff, E.M.* ; Pearson, E.R.* ; Diamant, M.*

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.

Diabetes 62, 3275-3281 (2013)

Verlagsversion

DOI

PMC

	Closed

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances β-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P ≤ 8.8 × 10(-7)). rs7202877 near CTRB1/2, a known diabetes risk locus, also associated with an absolute 0.51 ± 0.16% (5.6 ± 1.7 mmol/mol) lower A1C response to DPP-4 inhibitor treatment in G-allele carriers, but there was no effect on GLP-1 RA treatment in type 2 diabetic patients (n = 527). Furthermore, in pancreatic tissue, we show that rs7202877 acts as expression quantitative trait locus for CTRB1 and CTRB2, encoding chymotrypsinogen, and increases fecal chymotrypsin activity in healthy carriers. Chymotrypsin is one of the most abundant digestive enzymes in the gut where it cleaves food proteins into smaller peptide fragments. Our data identify chymotrypsin in the regulation of the incretin pathway, development of diabetes, and response to DPP-4 inhibitor treatment.

Impact Factor

Scopus SNIP

Scopus
Cited By

Altmetric

0.000

2.093